This page is available in multiple languages
Select Language

Galapagos celebrates 10-year listing anniversary by sounding gong


Galapagos NV (ticker symbol: GLPG) sounds the gong to celebrate 10 years as a listed company.

Ten years ago, on 5 May 2005, Galapagos completed its initial public offering with a dual listing in Amsterdam and Brussels. Since then, Galapagos has grown from 70 to over 400 employees and to €1.2 billion in market capitalization.

Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.

Galapagos forms part of the Amsterdam Midcap Index and Brussels BelMid Index. Galapagos recently reported positive results with its JAK1 inhibitor filgotinib in the DARWIN 1 and DARWIN 2 trials in nearly 900 rheumatoid arthritis patients worldwide; this was one of the research programs co-funded by the IPO in 2005.

For more information:

Download photo